The ω-6:ω-3 fatty acid ratio in Smoflipid® has not been shown to improve
clinical outcomes compared to other intravenous lipid emulsions.
Smoflipid® has been shown to improve EPA and DHA levels in adult patients7,23
– ESPEN states, "Addition of EPA and DHA to lipid emulsions has demonstrable effects on cell membranes and inflammatory processes." (Grade B)21
An additive in Smoflipid® that prevents the oxidation of lipids in the
formulation (~200 mg/L)7,18,23
– In clinical studies, Smoflipid® has been shown to increase plasma α-tocopherol levels7,18,23